A phase 1/2 open-label study to assess the safety, tolerability, and pharmacokinetics of intravenous infusion of MB07133 [Metabasis Therapeutics] in subjects with unresectable hepatocellular carcinoma and Child-Pugh Class A liver function.
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2011
At a glance
- Drugs MB 7133 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2007 Status changed from in progress to completed
- 12 Sep 2005 New trial record.